Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy

Background. Natalizumab is a highly effective treatment approved for multiple sclerosis (MS). The opening of the blood-brain barrier mediated by matrix metalloproteinases (MMPs) is considered a crucial step in MS pathogenesis. Our goal was to verify the utility of serum levels of active MMP-2 and MM...

Descripción completa

Detalles Bibliográficos
Autores principales: Castellazzi, Massimiliano, Bellini, Tiziana, Trentini, Alessandro, Delbue, Serena, Elia, Francesca, Gastaldi, Matteo, Franciotta, Diego, Bergamaschi, Roberto, Manfrinato, Maria Cristina, Volta, Carlo Alberto, Granieri, Enrico, Fainardi, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909921/
https://www.ncbi.nlm.nih.gov/pubmed/27340316
http://dx.doi.org/10.1155/2016/8434209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909921/
https://www.ncbi.nlm.nih.gov/pubmed/27340316
http://dx.doi.org/10.1155/2016/8434209

Ejemplares similares